Validating Aurora B as an anti-cancer drug target
نویسندگان
چکیده
منابع مشابه
Validating Aurora B as an anti-cancer drug target.
The Aurora kinases, a family of mitotic regulators, have received much attention as potential targets for novel anti-cancer therapeutics. Several Aurora kinase inhibitors have been described including ZM447439, which prevents chromosome alignment, spindle checkpoint function and cytokinesis. Subsequently, ZM447439-treated cells exit mitosis without dividing and lose viability. Because ZM447439 ...
متن کاملAurora kinases as an anti-cancer target.
The Aurora family of serine/threonine kinases plays an important role in chromosome alignment, segregation and cytokinesis during mitosis. Recent studies have found aberrant expression of Aurora kinases in a variety of human solid tumors and hematological malignancies, suggesting they have a role in carcinogenesis. This review highlights the function of Aurora kinases in the regulation of mitos...
متن کاملFLIP as an Anti-Cancer Therapeutic Target
Suppression of apoptosis is one of the hallmarks of carcinogenesis. Tumor cells endure apoptotic pressure by overexpressing several antiapoptotic proteins, and FLICE inhibitory protein (FLIP) is one of the important antiapoptotic proteins that have been shown to be overexpressed in various primary tumor cells. FLIP has two death-effector domains in tandem, mimicking the prodomain of procaspase-...
متن کاملp53 as a target for anti-cancer drug development.
Loss of p53 function compromises genetic homeostasis in cells exhibiting deregulated DNA replication and/or DNA damage, and prevents normal cytotoxic responses to cancer therapies. Genetic and pharmacological approaches are being developed with the ultimate goal of restoring or controlling p53 functions in cancer patients. Progress has recently been made in the clinical use of replication-defic...
متن کاملPYY3-36 as an anti-obesity drug target.
The neuropeptide Y (NPY)/peptide YY (PYY) system has been implicated in the physiology of obesity for several decades. More recently ignited enormous interest in PYY3-36, an endogenous Y2-receptor agonist, as a promising anti-obesity compound. Despite this interest, there have been remarkably few subsequent reports reproducing or extending the initial findings, while at the same time studies fi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Cell Science
سال: 2006
ISSN: 1477-9137,0021-9533
DOI: 10.1242/jcs.03145